ERBITUX CETUXIMAB

Serial Number 76670452
Registration 3333263
800

Registration Progress

Application Filed
Dec 18, 2006
Under Examination
Approved for Publication
Aug 8, 2007
Published for Opposition
Aug 28, 2007
Registered
Nov 13, 2007

Trademark Image

ERBITUX CETUXIMAB

Basic Information

Serial Number
76670452
Registration Number
3333263
Filing Date
December 18, 2006
Registration Date
November 13, 2007
Published for Opposition
August 28, 2007
Renewal Date
November 13, 2017
Drawing Code
3000

Status Summary

Current Status
Active
Status Code
800
Status Date
Nov 19, 2017
Registration
Registered
Classes
005

Rights Holder

ImClone LLC

16
Address
450 East 29th Street
New York, NY 10016

Ownership History

ImClone Systems Incorporated

Original Applicant
03
New York, NY

ImClone Systems Incorporated

Owner at Publication
03
New York, NY

ImClone Systems Incorporated

Original Registrant
03
New York, NY

ImClone LLC

New Owner After Registration #1
16
New York, NY

Legal Representation

Attorney
Bruce W. Longbottom

USPTO Deadlines

Next Deadline
844 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2007-11-13)
Due Date
November 13, 2027
Grace Period Ends
May 13, 2028

Application History

30 events
Date Code Type Description Documents
Nov 19, 2017 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Nov 19, 2017 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED Loading...
Nov 19, 2017 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) Loading...
Nov 19, 2017 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED Loading...
Oct 23, 2017 E89R I TEAS SECTION 8 & 9 RECEIVED Loading...
Nov 13, 2016 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED Loading...
Nov 22, 2013 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Nov 22, 2013 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Nov 21, 2013 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Nov 8, 2013 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Nov 8, 2013 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 8, 2013 815F I REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED Loading...
Jun 3, 2009 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 3, 2009 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 4, 2009 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Mar 21, 2008 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 13, 2007 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 28, 2007 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 8, 2007 NPUB O NOTICE OF PUBLICATION Loading...
May 22, 2007 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
May 21, 2007 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 16, 2007 ALIE A ASSIGNED TO LIE Loading...
May 16, 2007 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 15, 2007 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
May 15, 2007 CNEA O EXAMINERS AMENDMENT MAILED Loading...
Apr 16, 2007 CNRT F NON-FINAL ACTION MAILED Loading...
Apr 14, 2007 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 12, 2007 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 26, 2006 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Dec 22, 2006 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER
First Use Anywhere: Feb 19, 2004
First Use in Commerce: Feb 19, 2004

Additional Information

Color Claim
The color(s) blue, orange is/are claimed as a feature of the mark.
Other
The color blue appears in the literal portion of the mark; the color orange appears in the design element of the mark. The color white appears as background and is not a part of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
CETUXIMAB